Lisata Therapeutics, Inc. - Common Stock (LSTA)

1.1000
-0.0400 (-3.51%)
NASDAQ· Last Trade: Aug 5th, 2:48 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
These stocks are moving in today's after hours sessionchartmill.com
Via Chartmill · July 28, 2026
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Via Chartmill · July 21, 2026
The market is filled with gapping stocks in Tuesday's session.chartmill.com
Via Chartmill · July 21, 2026
Wondering what's happening in today's pre-market session?chartmill.com
Via Chartmill · July 21, 2026
Earnings Scheduled For November 6, 2025benzinga.com
Via Benzinga · November 6, 2025
Earnings Scheduled For August 7, 2025benzinga.com
Via Benzinga · August 7, 2025
Earnings Scheduled For May 8, 2025benzinga.com
Via Benzinga · May 8, 2025
Earnings Scheduled For February 27, 2025benzinga.com
Via Benzinga · February 27, 2025
Earnings Scheduled For November 12, 2024benzinga.com
Via Benzinga · November 12, 2024
Earnings Outlook For Lisata Therapeuticsbenzinga.com
Via Benzinga · November 11, 2024
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics (NASDAQ:LSTA)
Via Benzinga · July 9, 2026
In today's session, these stocks are experiencing unusual volume.chartmill.com
Via Chartmill · January 27, 2026
The trading volume of these stocks is deviating from the norm in today's session.chartmill.com
Via Chartmill · January 22, 2026
Lisata Shares Nearly Double On Buyout Offer: Here Are The Detailsstocktwits.com
Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.
Via Stocktwits · January 21, 2026
Lisata Therapeutics (NASDAQ:LSTA) Reports Narrower-Than-Expected Q3 2025 Losschartmill.com
Lisata Therapeutics reported a narrower-than-expected Q3 2025 loss, advancing its lead candidate, certepetide, with a cash runway into 2027.
Via Chartmill · November 6, 2025
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · November 4, 2025
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · July 21, 2025
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Salesbenzinga.com
Via Benzinga · January 22, 2025
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earningsbenzinga.com
Via Benzinga · January 22, 2025
US Stocks Higher; Netflix Profit Beats Estimatesbenzinga.com
Via Benzinga · January 22, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 22, 2025
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · January 22, 2025
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024investorplace.com
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 12, 2024
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacybenzinga.com
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing on detecting circulating tumor DNA.
Via Benzinga · July 18, 2024
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Via News Direct · May 13, 2024